

1 Acute and persistent symptoms in non-hospitalized PCR-confirmed 2 COVID-19 patients

3 Sofie Bliddal^{1,2}, Karina Banasik³, Ole Birger Pedersen⁴, Ioanna Nissen⁵, Lisa Cantwell³, Michael Schwinn⁵,
4 Morten Tulstrup^{6,7}, David Westergaard^{3,8,9}, Henrik Ullum^{10,11}, Søren Brunak³, Niels Tommerup¹², Bjarke
5 Feenstra¹³, Frank Geller¹³, Sisse Rye Ostrowski^{5,11}, Kirsten Grønbaek^{6,7,11}, Claus Henrik Nielsen^{2,11}, Susanne
6 Dam Nielsen^{11,14}, and Ulla Feldt-Rasmussen^{1,11*}

7

8 1. Department of Medical Endocrinology and Metabolism, Copenhagen University Hospital
9 (Rigshospitalet), Denmark.

10 2. Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen
11 University Hospital (Rigshospitalet), Denmark.

12 3. Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences,
13 University of Copenhagen, Denmark.

14 4. Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark

15 5. Department of Clinical Immunology, Copenhagen University Hospital (Rigshospitalet), Denmark

16 6. Department of Hematology, Rigshospitalet, Copenhagen, Denmark

17 7. Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of
18 Copenhagen, Copenhagen, Denmark

19 8. Recurrent Pregnancy Loss Unit, Capital Region, Copenhagen University Hospital, Rigshospitalet,
20 Fertility Clinic 4071, 2100 Copenhagen Ø, and Hvidovre Hospital, 2650 Hvidovre, Denmark

21 9. Methods and Analysis, Statistics Denmark, 2100 Copenhagen Ø, Denmark

22 10. Management section, Statens Serum Institut, Copenhagen, Denmark

23 11. Department of Clinical Medicine, Faculty of Health and Clinical Sciences, Copenhagen University,
24 Denmark.

25 12. Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark

26 13. Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 14. Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Denmark.

28

29 ¶These authors contributed equally to this work.

30 *Corresponding author: email: ufeldt@rh.dk (UFR)

31

32 Abstract

33 **Background:** Reports of persistent symptoms after hospitalization with COVID-19 have raised concern of a
34 “long COVID” syndrome. This study aimed at characterizing acute and persistent symptoms in non-
35 hospitalized patients with polymerase chain reaction (PCR) confirmed COVID-19.

36 **Methods:** Cohort study of 445 non-hospitalized participants identified via the Danish Civil Registration
37 System with a SARS-CoV-2-positive PCR-test and available biobank samples for genetic analyses.
38 Participants received a digital questionnaire on demographics and COVID-19-related symptoms. Persistent
39 symptoms: symptoms >four weeks (in sensitivity analyses >12 weeks).

40 **Results:** 445 participants were included, of whom 34% were asymptomatic. Most common acute symptoms
41 were fatigue, headache, and sneezing, while fatigue and reduced smell and taste were reported as most severe.
42 Persistent symptoms, most commonly fatigue and memory and concentration difficulties, were reported by
43 36% of 198 symptomatic participants with follow-up >four weeks. Risk factors for persistent symptoms
44 included female sex (women 44% vs. men 24%, odds ratio 2.7, 95%CI:1.4-5.1, p=0.003) and BMI (odds ratio
45 1.1, 95%CI:1.0-1.2, p=0.001).

46 **Conclusion:** Among non-hospitalized PCR-confirmed COVID-19 patients one third were asymptomatic while
47 one third of symptomatic participants had persistent symptoms illustrating the heterogeneity of disease
48 presentation. These findings should be considered in future health care planning and policy making related to
49 COVID-19.

50

51 **Introduction**

52 Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-
53 CoV-2), has by December 2020 affected more than 82 million people worldwide and has been associated with
54 2 million deaths leading to a global health and financial crisis [1]. Established risk factors related to dying with
55 the disease include high age, male sex and preexisting comorbidities [2,3,4]. A meta-analysis of 24,410
56 COVID-19 patients found that the most common symptoms were fever, cough, fatigue, and hyposmia [5].
57 However, not all exposed individuals catch the disease and not all who have the disease develop symptoms
58 [6,7]. Thus, there is a knowledge gap of individual resilience and risk factors determining the disease trajectory.

59 In the wake of the initial phase of the COVID-19 pandemic, several observational studies, patient groups and
60 case series have reported persistent symptoms including reduced respiratory capacity [8], fatigue and
61 hyposmia [9,10,11]. In a follow-up study of 143 Italians discharged after hospitalization due to COVID-19,
62 87.4% still experienced COVID-19-related symptoms at two months after symptom start, and more than half
63 of the patients reported persistent fatigue [12]. Similarly, Jacobs *et al* found that fatigue was the most prevalent
64 symptom 35 days post-hospitalization in 183 participants from the United States, and the majority of
65 participants reported reduced quality of life and both physical and mental health problems [13]. A recent
66 Chinese study presented 6-month follow-up data from 1,733 hospitalized patients, of whom 63% still
67 experienced fatigue and muscle weakness [14]. Clinical and public health interests are therefore no longer
68 limited to information on mortality and clinical outcomes in hospitalized patients, but also to recovery and
69 long-term consequences of COVID-19 post-hospitalization. Among other initiatives, this has led to the Post-
70 Hospitalization COVID-19 study (PHOSP-COVID) in the United Kingdom aiming at long-term follow-up of
71 10,000 patients discharged after hospitalization due to COVID-19 [15]. The increasing awareness of persistent
72 symptoms among COVID-19 patients has even led to the designation “long COVID” which is yet to be clearly
73 defined [16,17,18]. A recent first draft guideline on long-term effects of COVID-19 published by the National
74 Institute of Health and Care Excellence (NICE) suggests to use the definition “ongoing symptomatic COVID-
75 19” for symptoms lasting between 4 and 12 weeks after the acute onset and “post-COVID-19-syndrome” for
76 symptoms lasting more than 12 weeks [19].

77 Most studies on COVID-19 symptoms have recruited participants among hospitalized patients or patients
78 attending outpatient clinics or specialized units, or support groups dealing with the consequences of COVID-
79 19 [5,9,20,21]. This confers a selection bias likely overestimating the true prevalence of symptoms and
80 symptom severity. Thus, there is an academic knowledge gap in symptomatology among unselected non-
81 hospitalized patients.

82 The aim of the present study was to determine the nature and prevalence of acute and persistent symptoms in
83 non-hospitalized patients with COVID-19 confirmed by a positive SARS-CoV-2 PCR.

84

85 **Materials and Methods**

86 **Participants**

87 All individuals registered in the Danish Civil Registration System with a COVID-19 diagnosis confirmed by
88 polymerase chain reaction (PCR) for SARS-CoV-2 by August 12th 2020 and an available biobank sample for
89 genetic analyses (n=4,421) were invited via the national digital postbox, e-Boks, to participate in a study on
90 genetics in COVID-19 and related outcomes. The e-Boks is a secure digital postbox used by 92.1% of the
91 Danish adult population by the second quarter of 2020 [22]. A list of SARS-CoV-2 positive individuals was
92 obtained from the Danish Microbiology (MiBa) database, which holds data for all SARS-CoV-2 PCR-tests in
93 Denmark, provided by the Danish Health Data Authority [23,24]. Relevant biobank samples with sufficient
94 material for genetic analyses were identified among stored samples in the Danish National Biobank or the
95 Copenhagen Hospital Biobank [25,26].

96 Invitations were sent to participants via e-Boks between June 24th and August 15th 2020 together with written
97 project information and a link to a questionnaire on demographic data and symptomatology related to COVID-
98 19. Interested participants could contact a call center between July 27th and August 28th 2020 to receive oral
99 information on the project and provide oral consent prior to receiving a digital link for written consent. The
100 last questionnaire was received digitally by October 31st 2020.

101 **Inclusion criteria**

102 All individuals in the Danish Civil Registration System with a PCR-confirmed positive test for SARS-CoV-2
103 and an available biobank sample for genetic analyses with no history of hospitalization due to COVID-19 were
104 eligible for this study (n=4,421). Hospitalization due to COVID-19 was defined as a hospital admission lasting
105 longer than 12 hours within 14 days of a positive PCR-test for SARS-CoV-2. Date of COVID-19 diagnosis
106 and hospitalization status were accessed through the national register for COVID-19 surveillances (EpiMiBa).
107 Non-hospitalized participants with a valid written consent and a completed questionnaire were included in this
108 study.

109 **Questionnaire**

110 All participants received a link in their e-Boks to a questionnaire with a large number questions on
111 demographic data as well as history and symptoms related to COVID-19. The questionnaire was to a large
112 extent based on a previously validated questionnaire used as part of the Danish Blood Donor Study [27].
113 Questions on lifestyle factors, demographics and co-morbidities included smoking status, height and weight,
114 occupation, educational level, and the possibility to select the following chronic diseases (using layman terms):
115 Asthma, allergy (other than asthma), diabetes mellitus, hyperthyroidism, hypothyroidism, high blood pressure,
116 heart attack, chest pain (angina pectoris), stroke, chronic bronchitis or big lungs or smokers lungs (emphysema,
117 COPD), osteoarthritis, rheumatoid arthritis, osteoporosis, cancer, other.

118 Queries on symptomatology related to COVID-19 included the questions “Have you had a feeling of being ill
119 in the period since February 1st 2020?” and if “yes” the following symptoms were listed with answer options
120 of “No”, “Yes, a little”, “Yes, some”, “Yes, a lot”, “Don’t know”: Fever, chills, runny or stuffy nose, reduced
121 sense of smell, reduced sense of taste, sneezing, sore throat, coughing, shortness of breath, headache, muscle
122 and joint pain, chest pain, tiredness and exhaustion [fatigue], difficulties concentrating or remembering, lack
123 of appetite, coloured sputum, red runny eyes, nausea, vomiting, diarrhoea, stomach pain, other. To clarify
124 persistence of symptoms, the questionnaire included the question “Do you still have symptoms” and if the
125 participant answered “yes”, the same list of symptoms was provided albeit without the option of ranking the
126 degree of symptoms.

127 Symptoms commencing between 28 days before the positive SARS-CoV-2 PCR-test result and 14 days after
128 the test result were included as COVID-19-related symptoms (Supplementary Fig. S1 online). Persistent
129 symptoms were defined as symptoms lasting more than four weeks; these could be ongoing symptoms at the
130 time of filling in the questionnaire in case of a follow-up time of more than four weeks from symptom onset.
131 Alternatively, a stop date could be given in case of a reported symptom lasting more than four weeks from
132 symptom onset to symptom stop. In sensitivity analyses, persistent symptoms lasting more than 12 weeks were
133 explored based on the same selection criteria (12 weeks instead of four weeks). These time limits were in
134 accordance with the time frame for ongoing symptomatic COVID-19 and post-COVID-19-syndrome,
135 respectively, suggested by the National Institute for Health and Care Excellence in the United Kingdom [19].

136 **Statistics**

137 Demographic data were presented as appropriate by means and standard deviations (SD) or medians and inter-
138 quartile range (IQR). Logistic regression analyses included as covariates: sex (male-female), age, BMI,
139 smoking status (non-smoker vs. ever smoker), comorbidity (yes-no based on composite scores of self-reported
140 chronic disease), work in the health care sector (yes-no), and time to questionnaire (weeks). The latter was
141 included to account for any potential recall bias as the time periods between the PCR test and the questionnaire
142 (in analyses of asymptomatic vs. symptomatic participants) or between the symptom start and the questionnaire
143 (in analyses of persistent vs. no persistent symptoms among symptomatic individuals). Among the health care
144 workers, almost all reported having patient contact [not specified if COVID-related] and thus patient contact
145 was not included in the model. In the logistic regression analyses of risk of acute and persistent symptoms, we
146 used a composite score (any symptom vs no symptom) across all acute and persistent symptoms, respectively.
147 The composite score for acute symptoms included any symptom, regardless of reported severity. P-values
148 reported are based on Welch Two Sample t-test for normally distributed traits and Fisher's Exact for
149 categorical traits. All statistical analyses and preparation of figures were performed by R version 3.5.0 (the R
150 foundation, www.r-project.org).


151 **Ethics**

152 The study was part of the “Epidemiology and Genetics of COVID-19” study approved by the National
153 Committee on Health Research Ethics (ID: NVK 2003947) and by the Data Protection Agency (ID: P-2020-
154 356). All participants provided oral and written consent to participate.

155 Results

156 A total of 445 Danish non-hospitalized COVID-19 participants were included (see Fig. 1 for flow chart of the
157 inclusion process).

Figure 1. Flowchart of inclusion process



Inclusion process of Danes with PCR-confirmed SARS-CoV-2 in study of symptoms among non-hospitalized patients.

Abbreviations: e-Boks, secure digital postbox used by 92% of Danes. PCR, polymerase chain reaction. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

159 Most participants had been tested during the Spring of 2020 (Table 1). More women than men participated in
160 the study and significantly more women worked in the health care sector and had patient contact (not specified
161 if COVID-related). Also, the median date for PCR-testing of the included women was one month earlier than
162 that of men (Table 1). There were no other significant differences in demographic data between men and
163 women (Table 1). Less than half of the participants reported preexisting comorbidities; most commonly allergy
164 (28%), hypertension (15%), osteoarthritis (17%), and asthma (8%) (see Supplementary Fig. S2 online).

165

166 **Acute symptoms**

167

168 Completely asymptomatic COVID-19 was reported by 34% of participants. There were no significant
169 differences in sex, smoking status, comorbidities, health care worker status or BMI between those reporting
170 symptoms and those without symptoms. Asymptomatic participants had more often been tested towards the
171 end of the study inclusion period (weeks from PCR to questionnaire; adjusted odds ratio (OR) 1.06
172 95%CI:1.02-1.09, $p=0.0008$) (depicted in Supplementary Fig. S3 online), and were slightly older (OR for
173 symptoms 0.98 (0.97-0.99), $p=0.004$).

174 Among the 238 participants experiencing symptoms, 55% of women and 52% of men had a sudden onset of
175 symptoms arising within a few hours. Characteristics of symptomatic participants are presented in Table 2.
176 Significantly more symptomatic women than men were working in the health care system, had contact with
177 patients in their work and had been tested slightly earlier in the year (Table 2). The most common symptoms
178 in the acute phase of COVID-19 were fatigue (95%), headache (82%), and sneezing (76%) (Fig. 2A). However,
179 the symptoms most often reported as being severe were reduced smell, fatigue, and reduced taste (Fig. 2A).
180 Excluding all participants with comorbidities did not change the symptom presentation (Fig. 2B).

181

182


183

184


185

186 **Figure 2. Symptom presentation and severity during acute COVID-19 in non-hospitalized patients**

A



B



187


188 Symptom pattern and severity reported in relation to the acute phase of COVID-19 by non-hospitalized
 189 participants with a SARS-CoV-2-positive PCR test. Only participants with symptom start between 28 days
 190 before and 14 days after the PCR-test were included. Figure A, all symptomatic participants (n=238). Figure
 191 B, symptomatic participants without comorbidities (n=105).

192 Abbreviations: PCR, polymerase chain reaction. SARS-CoV-2, severe acute respiratory syndrome coronavirus
 193 2.

194 **Persistent symptoms**

195 Most symptomatic participants experienced symptom cessation within two weeks (n=137, women in median
196 14 days (range:1-112), men in median 12 days (1-138)). Ongoing symptoms at the time of filling in the
197 questionnaire were reported by more than 35% of participants (median time from symptom start 90 days (range
198 5-197)). Follow-up for more than four weeks was available from 198 symptomatic participants among whom
199 persistent symptoms were reported by 36% (44% of women and 24% of men). The most common persistent
200 symptoms were fatigue (16%), concentration or memory difficulties (13%), reduced sense of smell (10%), and
201 shortness of breath (10%) (Fig. 3). Among participants with more than 12 weeks of follow-up since symptom
202 start (n=129), 40% (48% of women and 23% of men) still had symptoms, especially fatigue (16%) and
203 concentration difficulties (13%), following the same pattern as those with a shorter follow-up period (Fig. 3).

204 **Figure 3. Persistent symptoms in COVID-19 at 4 and 12 weeks**



205

206 Persistent symptoms after COVID-19. In dark blue, persistent symptoms for more than four weeks in the 198
207 non-hospitalized participants with symptoms and a follow-up time of more than four weeks and in light blue,
208 persistent symptoms for more than 12 weeks in the 129 non-hospitalized participants with symptoms and a
209 follow-up time of more than 12 weeks.
210

211

212 The risk of persistent symptoms more than four weeks after symptom start was significantly increased in
213 women compared to men (OR 2.7 95%CI:1.4-5.2, $p=0.003$ (Table 3)). Furthermore, there was an increased
214 risk of persistent symptoms with increasing BMI (OR 1.1 95%CI:1.0-1.2, $p=0.001$ (Table 3)). No other
215 covariates were significantly associated with the risk of persistent symptoms. Female sex and BMI were also
216 the only significant risk factors for persistent symptoms in the 129 participants with a follow-up period of more
217 than 12 weeks (see supplementary Table S1 available online).


218 More women than men worked in the health care sector (table 1 and 2). Thus, we re-ran analyses of risk factors
219 for persistent symptoms by only including the 117 women with follow-up of more than four weeks. Doing so,
220 BMI was still a significant risk factor (adjusted OR 1.2 95%CI:1.1-1.3, $p=0.003$), but being a health care
221 worker was not (OR 1.5 95%CI:0.6-3.8, $p=0.39$).

222 Furthermore, we depicted acute and persistent symptoms according to sex (Fig. 4). Men and women had a
223 similar prevalence of fatigue in the acute phase (Fig. 4 left hand side). In participants with persistent symptoms,
224 fatigue was the most common persistent symptom in both men and women, but the prevalence of persistent
225 fatigue was almost twice as high in women compared to men (28% vs. 15%, OR 2.2 95%CI:1.0-4.7, $p=0.05$,
226 right hand side of Fig. 4).

227

228

229 **Figure 4. Acute and persistent symptoms in non-hospitalized men and women with COVID-19**



230

231 The percentage of acute (red panel to the left) and persistent (blue panel to the right) symptoms in non-
 232 hospitalized COVID-19 participants according to sex. Persistent symptoms were defined as lasting more than
 233 four weeks. A, prevalence of reported acute (total n=148) and persistent symptoms (total n=126) in women.
 234 B, prevalence of reported acute (total n=90) and persistent symptoms (total n=72) in men.

235

236 Discussion

237 The present study demonstrated a high prevalence of persistent symptoms in non-hospitalized patients with
238 COVID-19 confirmed by SARS-CoV-2 PCR-testing. The most common persistent symptoms were fatigue
239 and memory and concentration difficulties with a higher risk in women. Furthermore, there was an equally
240 high prevalence of asymptomatic COVID-19 participants.

241 Unlike most previous studies on COVID-19-related symptoms an important strength of the present study was
242 the recruitment of non-hospitalized participants with a positive SARS-CoV-2 PCR-test. Thus, we were able to
243 depict variations in symptoms even among non-hospitalized participants with a confirmed COVID-19
244 diagnosis. Contrary to studies relying solely on information gathered through questionnaire data, our use of
245 national register data on SARS-CoV-2 PCR tests and hospitalization strengthens the validity of the study
246 results. However, our study finding of women being at higher risk of persistent symptoms may be biased by
247 the fact that more asymptomatic individuals, especially men, were included towards the end of the inclusion
248 period and were slightly older. This likely reflects both an altered test strategy in Denmark with easier access
249 to targeted testing for mild cases of COVID-19 and screening of close contacts, and a survival bias with a
250 higher risk of hospitalization among older citizens and symptomatic men. In addition, more women worked in
251 the health care sector with patient contact and although this was not associated with an increased risk of
252 persistent symptoms in the present study, larger studies are needed to clarify if the increased risk of persistent
253 symptoms among women could be confounded by specific lines of work. Finally, all studies of COVID-19-
254 related symptoms suffer from an inherent likelihood of attracting participants with a personal experience of
255 severe or persistent symptoms thus risking an overestimation of the true prevalence of persistent symptoms. A
256 similar selection bias may be present in our study, however, likely reduced compared to most studies
257 specifically addressing COVID-19-related symptoms because we specifically invited participants to a study
258 on genetics and not symptoms.

259

260 Our finding of fatigue as the most prevalent persistent symptom matches previous studies among post-
261 hospitalized COVID-19 patients suffering from fatigue [9,12,28,29]. To our knowledge, few studies have been
262 published on persistent symptoms in non-hospitalized patients with positive SARS-CoV-2 PCR-tests. Among

263 292 participants interviewed by phone at a median of 16 days post-testing, Tenforde *et al* found 35% of
264 participants with acute symptoms to still be experiencing symptoms (especially coughing, fatigue and
265 shortness of breath) [30]. In a study of 180 participants (8 of whom had been hospitalized) interviewed during
266 the acute phase of disease and at follow-up phone calls, persistent symptoms were reported by 53% of
267 symptomatic participants at a mean follow-up time of 125 days (most often fatigue, loss of smell and taste,
268 and arthralgias) [31]. Larger survey-based studies on COVID-19-related symptoms in a multitude of
269 participants with self-reported COVID-19 are available online, although not yet peer-reviewed (Table 4
270 presents an overview of studies) [32,33,34,35,36,37]. Characteristic for most of these studies is the acceptance
271 of self-reported COVID-19 status by participants without laboratory confirmation of COVID-19-status, and
272 recruitment of participants with the specific aim of COVID-19 symptom reporting likely inferred a substantial
273 selection bias. However, most studies do report fatigue, concentration problems and loss of smell and taste as
274 the most common persistent symptoms, which is comparable to our findings in PCR-confirmed COVID-19
275 non-hospitalized participants. Thus, our study provides substantial laboratory- and registry-confirmed
276 evidence in support of these symptoms being part of a “long COVID”-syndrome existing even in non-
277 hospitalized COVID-19 patients.

278

279 Why SARS-CoV-2 carries a high risk of persistent symptoms, especially in women, is an urgent research
280 question. Suggested mechanisms fall into two categories of either direct effects from the virus or indirect
281 effects caused by immune responses to the virus [38]. While persistent symptoms including chronic fatigue
282 are well-described in other pulmonary infections such as SARS and pneumonia, SARS-CoV-2 may differ in
283 its multi-organ-affection and high contagiousness [38,39,40,41]. The female preponderance bears
284 resemblance to that of many autoimmune diseases [42]. Unfortunately, the present study did not have
285 laboratory data to assess either initial or persistent immunological response against SARS-CoV-2 and did not
286 have data for retesting for SARS-CoV-2 to ascertain resolution of the viral load in participants with persistent
287 symptoms. However, previous studies have found a poor correlation between the risk of persistent symptoms
288 and objective measures of disease despite performing a wide range of clinical and laboratory tests in COVID-
289 19 patients either during the acute phase or at follow-up [9,28]. Also, a negative SARS-CoV-2 PCR-test as a
290 sign of recovery has been criticized for not corresponding to the patients’ perception of (or lack of) recovery

291 [33,35]. Thus, detailed laboratory data and functional studies are urgently needed to understand the
292 immunological component of long COVID.

293

294 An important question arising from the present and other studies of long COVID is how to manage these
295 patients with persistent symptoms. Previous studies of chronic fatigue have shown uncertain benefit of
296 treatment such as exercise, cognitive behavioral therapy, and rehabilitation initiatives, and are, nevertheless,
297 not necessarily compatible with post-COVID fatigue [43,44,45]. Several specific management initiatives are
298 emerging for “long COVID” as well as guideline initiatives by the National Institute for Health and Care
299 Excellence in United Kingdom, and guidance material for self-rehabilitation after COVID-19 released by the
300 World Health Organization [9,12,19,46]. Some have argued for the importance of involving general
301 practitioners in the management of this syndrome [47] and some have advocated for the importance of
302 including patients in emerging new strategies [16,48]. A subset of patients has yet to recover after months of
303 symptoms and those patients may need long-term follow-up at specialized units. Thus, an important aspect of
304 future studies on this matter is to identify patients at risk of long-term symptoms. The present study suggests
305 that up to 40% of non-hospitalized previously healthy patients will experience some degree of persistent
306 symptoms with an increased risk in women. Larger studies of big data including real-time symptom reporting
307 will aid in determining risk factors and predicting disease trajectories [34,49]. The mounting evidence of “long
308 COVID” calls for active policy making to secure prevention and early detection, facilitate optimal treatment
309 and support rehabilitation [16,38].

310

311 Equally important may be the high proportion of asymptomatic COVID-19 individuals. In the present study
312 34% of non-hospitalized PCR-confirmed SARS-CoV-2-positive participants reported no symptoms in the
313 acute phase of the disease. However, the overall prevalence of asymptomatic COVID-19 was similar to that
314 estimated in Danish health care workers (assessed by IgM and IgG antibodies against SARS-CoV-2) of 46.5%
315 [50]. Similarly, a study of the Icelandic population found that 43% were asymptomatic at time of a positive
316 SARS-CoV-2 PCR test among participants included in a population screening unlike targeted testing of
317 severely symptomatic individuals [51]. Furthermore, the COVID Symptom Score study prospectively
318 monitored more than 2 million citizens in UK, US and Sweden. In a subset of 26,495 participants with a self-
319 reported positive SARS-CoV-2 PCR-test, 55.3% were asymptomatic [34,49] [numbers deduced from

320 supplementary files]. Although some studies reported a lower prevalence [31], there did seem to be a general
321 agreement on a true high prevalence of asymptomatic COVID-19. In a recent analytical model based on the
322 assumption that 30% of COVID-patients may be asymptomatic, Johansson *et al* found that asymptomatic
323 individuals would carry 50% of all transmissions [52]. This has important implications for disease control and
324 stresses the need for active tracing and testing of close contacts as part of disease control.

325

326 In conclusion, even among non-hospitalized PCR-confirmed SARS-CoV-2-positive participants, more than
327 one third reported persistent symptoms after four and 12 weeks, respectively. The most prevalent persistent
328 symptoms were fatigue and memory and concentration difficulties. Contrary to this, 34% of non-hospitalized
329 patients were asymptomatic in the acute phase of the disease stressing the importance of testing near contacts.
330 The high prevalence of both patients with persistent symptoms and of asymptomatic patients bear witness to
331 the heterogeneity of the disease presentation. Although data should be reproduced due to possible limitations
332 of survival or recall bias, these findings should be taken into account in future health care planning and policy
333 making related to COVID-19 prevention, detection, treatment and follow-up.

334 **References**

- 335 1. Johns Hopkins University. The Johns Hopkins Coronavirus Resource Center. <https://coronavirus.jhu.edu/map.html>. (2020).
336
- 337 2. Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus Disease
338 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese
339 Center for Disease Control and Prevention. *JAMA*. **323**, 1239-1242 (2020).
- 340 3. Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
341 *Lancet*. **395**, 497-506 (2020).
- 342 4. Zheng, Z. *et al.* Risk factors of critical & mortal COVID-19 cases: A systematic literature review and
343 meta-analysis. *J. Infect.* **81**, e16-e25 (2020).
- 344 5. Grant, M. C. *et al.* The prevalence of symptoms in 24,410 adults infected by the novel coronavirus
345 (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9
346 countries. *PLoS. One*. **15**, e0234765 (2020).
- 347 6. Kronbichler, A. *et al.* Asymptomatic patients as a source of COVID-19 infections: A systematic review
348 and meta-analysis. *Int. J. Infect. Dis.* **98**, 180-186 (2020).
- 349 7. Arons, M. M. *et al.* Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing
350 Facility. *N. Engl. J. Med.* **382**, 2081-2090 (2020).
- 351 8. Fraser, E. Long term respiratory complications of covid-19. *BMJ*. **370**, m3001 (2020).
- 352 9. Townsend, L. *et al.* Persistent fatigue following SARS-CoV-2 infection is common and independent of
353 severity of initial infection. *PLoS. One*. **15**, e0240784 (2020).
- 354 10. Hopkins, C. *et al.* Six month follow-up of self-reported loss of smell during the COVID-19 pandemic.
355 *Rhinology*. doi: 10.4193/Rhin20.544. Online ahead of print (2020).
- 356 11. Fjaeldstad, A. W. Prolonged complaints of chemosensory loss after COVID-19. *Dan. Med. J.* **67** (2020).
- 357 12. Carfi, A., Bernabei, R., & Landi, F. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*.
358 **324**, 603-605 (2020).
- 359 13. Jacobs, L. G. *et al.* Persistence of symptoms and quality of life at 35 days after hospitalization for
360 COVID-19 infection. *PLoS. One*. **15**, e0243882 (2020).
- 361 14. Huang, C. *et al.* 6-month consequences of COVID-19 in patients discharged from hospital: a cohort
362 study. *Lancet*. **Published Online January 8, 2021** , 1-12 (2021).
- 363 15. PHOSP-COVID consortium & Leicester University. The Post-hospitalisation COVID-19 study (PHOSP-
364 COVID). <https://www.phosp.org/>. (2020).
- 365 16. The Lancet. Facing up to long COVID. *Lancet*. **396**, 1861 (2020).
- 366 17. BMJ. Long covid: How to define it and how to manage it. <https://www.bmj.com/content/370/bmj.m3489>. doi: <https://doi.org/10.1136/bmj.m3489> (2020).
367

- 368 18. Nature. Long COVID: let patients help define long-lasting COVID symptoms. *Nature*. **586**, 170 (2020).
- 369 19. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term
370 effects of COVID-19. [https://www.nice.org.uk/guidance/ng188/chapter/1-Identifying-people-](https://www.nice.org.uk/guidance/ng188/chapter/1-Identifying-people-with-ongoing-symptomatic-COVID-19-or-post-COVID-19-syndrome)
371 [with-ongoing-symptomatic-COVID-19-or-post-COVID-19-syndrome](https://www.nice.org.uk/guidance/ng188/chapter/1-Identifying-people-with-ongoing-symptomatic-COVID-19-or-post-COVID-19-syndrome). (2020).
- 372 20. Meys, R. *et al.* Generic and Respiratory-Specific Quality of Life in Non-Hospitalized Patients with
373 COVID-19. *J. Clin. Med.* **9**, 3993 (2020).
- 374 21. Ladds, E. *et al.* Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and
375 draft quality principles for services. *BMC. Health Serv. Res.* **20**, 1144 (2020).
- 376 22. The Danish Digitization Agency. Statistics on Digital Post. [https://digst.dk/it-loesninger/digital-](https://digst.dk/it-loesninger/digital-post/om-loesningen/tal-og-statistik-om-digital-post/)
377 [post/om-loesningen/tal-og-statistik-om-digital-post/](https://digst.dk/it-loesninger/digital-post/om-loesningen/tal-og-statistik-om-digital-post/). (2020).
- 378 23. Voldstedlund, M., Haarh, M., & Molbak, K. The Danish Microbiology Database (MiBa) 2010 to 2013.
379 *Euro. Surveill.* **19**, 20667 (2014).
- 380 24. Statens Serum Institut. the Danish Microbiology Database. <https://miba.ssi.dk/service/english>. (2021).
- 381 25. Statens Serum Institut. The Danish National Biobank. <https://www.danishnationalbiobank.com/>.
382 (2020).
- 383 26. The Capital Region of Denmark. The Copenhagen Hospital Biobank. [https://www.regionh.](https://www.regionh.dk/forskning-og-innovation/Region-Hovedstadens-biobank/Sider/default.aspx)
384 [dk/forskning-og-innovation/Region-Hovedstadens-biobank/Sider/default.aspx](https://www.regionh.dk/forskning-og-innovation/Region-Hovedstadens-biobank/Sider/default.aspx). (2020).
- 385 27. Pedersen, O. B. *et al.* SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A
386 cross-sectional study. *Clin. Infect. Dis.* Online ahead of print (2020).
- 387 28. van den Borst, B. *et al.* Comprehensive health assessment three months after recovery from acute
388 COVID-19. *Clin. Infect. Dis.* Online ahead of print (2020).
- 389 29. Mandal, S. *et al.* 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging
390 abnormalities following hospitalisation for COVID-19. *Thorax*. Online ahead of print (2020).
- 391 30. Tenforde, M. W. *et al.* Symptom Duration and Risk Factors for Delayed Return to Usual Health Among
392 Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States,
393 March-June 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 993-998 (2020).
- 394 31. Petersen, M. S. *et al.* Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized
395 patients. *Clin. Infect. Dis.* Online ahead of print (2020).
- 396 32. Cirulli, E. T. *et al.* Long-term COVID-19 symptoms in a large unselected population. [https://www.](https://www.medrxiv.org/content/10.1101/2020.10.07.20208702v3)
397 [medrxiv.org/content/10.1101/2020.10.07.20208702v3](https://www.medrxiv.org/content/10.1101/2020.10.07.20208702v3). (2020).
- 398 33. Davis, H. E. *et al.* Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and
399 Their Impact. <https://www.medrxiv.org/content/10.1101/2020.12.24.20248802v2>. (2020).
- 400 34. Sudre, C. H. *et al.* Attributes and predictors of Long-COVID: analysis of COVID cases and their
401 symptoms collected by the Covid Symptoms Study App. [https://www.medrxiv.org/content/10.](https://www.medrxiv.org/content/10.1101/2020.10.19.20214494v2)
402 [1101/2020.10.19.20214494v2](https://www.medrxiv.org/content/10.1101/2020.10.19.20214494v2). (2020).

- 403 35. Patient-Led Research for COVID-19. Report: What Does COVID-19 Recovery Actually Look Like?
404 <https://patientresearchcovid19.com/research/report-1/>. (2021).
- 405 36. Goertz, Y. M. J. *et al.* Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19
406 syndrome? *ERJ. Open. Res.* **6**, doi.org/10.1183/23120541.00542-2020 (2020).
- 407 37. Walsh-Messinger, J. *et al.* The Kids Are Not Alright: A Preliminary Report of Post-COVID Syndrome in
408 University Students. <https://www.medrxiv.org/content/10.1101/2020.11.24.20238261v2.full.pdf>. (2020).
409
- 410 38. Nature Medicine. Meeting the challenge of long COVID. *Nat. Med.* **26**, 1803 (2020).
- 411 39. Metlay, J. P. *et al.* Measuring symptomatic and functional recovery in patients with community-acquired
412 pneumonia. *J. Gen. Intern. Med.* **12**, 423-430 (1997).
- 413 40. Lam, M. H. *et al.* Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors:
414 long-term follow-up. *Arch. Intern. Med.* **169**, 2142-2147 (2009).
- 415 41. Tansey, C. M. *et al.* One-year outcomes and health care utilization in survivors of severe acute
416 respiratory syndrome. *Arch. Intern. Med.* **167**, 1312-1320 (2007).
- 417 42. Billi, A. C., Kahlenberg, J. M., & Gudjonsson, J. E. Sex bias in autoimmunity. *Curr. Opin. Rheumatol.*
418 **31**, 53-61 (2019).
- 419 43. Turner-Stokes, L. & Wade, D. T. Updated NICE guidance on chronic fatigue syndrome. *BMJ.* **371**,
420 m4774 (2020).
- 421 44. Larun, L., Brurberg, K. G., Odgaard-Jensen, J., & Price, J. R. Exercise therapy for chronic fatigue
422 syndrome. *Cochrane. Database. Syst. Rev.* **10**, CD003200 (2019).
- 423 45. Vink, M. & Vink-Niese, A. Could Cognitive Behavioural Therapy Be an Effective Treatment for Long
424 COVID and Post COVID-19 Fatigue Syndrome? Lessons from the Qure Study for Q-Fever
425 Fatigue Syndrome. *Healthcare. (Basel).* **8**, 552 (2020).
- 426 46. World Health Organization. Support for Rehabilitation: Self-Management after COVID-19 Related
427 Illness. <https://www.who.int/publications/m/item/support-for-rehabilitation-self-management-after-covid-19-related-illness>. (2020).
428
- 429 47. Greenhalgh, T., Knight, M., A'Court, C., Buxton, M., & Husain, L. Management of post-acute covid-19
430 in primary care. *BMJ.* **370**, m3026 (2020).
- 431 48. Gorna, R. *et al.* Long COVID guidelines need to reflect lived experience. *Lancet.* (2020).
- 432 49. Drew, D. A. *et al.* Rapid implementation of mobile technology for real-time epidemiology of COVID-
433 19. *Science.* **368**, 1362-1367 (2020).
- 434 50. Iversen, K. *et al.* Risk of COVID-19 in health-care workers in Denmark: an observational cohort study.
435 *Lancet Infect. Dis.* **20**, 1401-1408 (2020).
- 436 51. Gudbjartsson, D. F. *et al.* Spread of SARS-CoV-2 in the Icelandic Population. *N. Engl. J. Med.* **382**,
437 2302-2315 (2020).

- 438 52. Johansson, M. A. *et al.* SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. *JAMA*
439 *Netw. Open.* **4**, e2035057 (2021).
440
441

442 **Acknowledgements**

443 We highly appreciate our collaboration with the Danish COVID-19 Genetic Consortium (Supplementary
444 Appendix 1 online). Work related to the present study was supported by a grant from Sygesikring Danmark
445 (2020-0178) to the Danish COVID-19 Genetic Consortium and by the Independent Research Fund Denmark
446 (0216-00014B to NT). KB, LC, DW, MS and SB (Brunak) acknowledge the Novo Nordisk Foundation (grants
447 NNF17OC0027594 and NNF14CC0001). KG was supported by a grant from the European Hematology
448 Association. SDN received research grants from Novo Nordic Foundation, FSS, Lundbeck Foundation, and
449 Rigshospitalet Research Council. UFR's research salary was supported by a research grant from The Kirsten
450 and Freddy Johansen's Fund. The funding sources had no impact on the planning or conduction of the study
451 or of any work related to this manuscript.

452 **Author contributions**

453 SB and KB planned and conducted the analyses and drafted the manuscript and revisions. IN, HU, SDN,
454 OBP, SB and MT contributed to the participant inclusion. OBP, SDN, and UFR developed the questionnaire.
455 MS was in charge of project data management. All coauthors contributed to the conception or design of the
456 work, or the acquisition, analysis, or interpretation of data, as well as reviewed and approved the content of
457 the manuscript.

458 **Additional Information**

459 The authors declare no competing interests.

460 **Data Availability**

461 The data that support the findings of this study are available from The Danish COVID-19 Genetic
462 Consortium but restrictions apply to the availability of data used under license for the current study, and thus
463 are not publicly available. Data are however available from the authors upon reasonable request and with
464 permission from The Danish COVID-19 Genetic Consortium under Danish legislation.

465

466 **Figure legends**

467

468 **Figure 1. Flowchart of inclusion process**

469 Inclusion process of Danes with PCR-confirmed SARS-CoV-2 in study of symptoms among non-
470 hospitalized patients.

471 Abbreviations: e-Boks, secure digital postbox used by 92% of Danes. PCR, polymerase chain reaction.

472 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

473

474 **Figure 2. Symptom presentation and severity during acute COVID-19 in non-hospitalized patients**

475 Symptom pattern and severity reported in relation to the acute phase of COVID-19 by non-hospitalized
476 participants with a SARS-CoV-2-positive PCR test. Only participants with symptom start between 28 days
477 before and 14 days after the PCR-test were included. Figure A, all symptomatic participants (n=238). Figure
478 B, symptomatic participants without comorbidities (n=105).

479 Abbreviations: PCR, polymerase chain reaction. SARS-CoV-2, severe acute respiratory syndrome coronavirus
480 2.

481

482 **Figure 3. Persistent symptoms in COVID-19 at 4 and 12 weeks**

483 Persistent symptoms after COVID-19. In dark blue, persistent symptoms for more than four weeks in the 198
484 non-hospitalized participants with symptoms and a follow-up time of more than four weeks and in light blue,
485 persistent symptoms for more than 12 weeks in the 129 non-hospitalized participants with symptoms and a
486 follow-up time of more than 12 weeks.

487

488 **Figure 4. Acute and persistent symptoms in non-hospitalized men and women with COVID-19**

489 The percentage of acute (red panel to the left) and persistent (blue panel to the right) symptoms in non-
490 hospitalized COVID-19 participants according to sex. Persistent symptoms were defined as lasting more than
491 four weeks. A, prevalence of reported acute (total n=148) and persistent symptoms (total n=126) in women.
492 B, prevalence of reported acute (total n=90) and persistent symptoms (total n=72) in men.

493 **Tables**

494

495 **Table 1. Characteristics of participants**

	Women (n=245)	Men (n=191)	p-value
Age (mean, SD)	45.6 (16.1)	48.7 (16.7)	0.04
BMI (median, IQR)	24.7 (6.9)	25.9 (4.6)	0.42
Smoking (ever, %)	14.2	16.2	0.59
Comorbidity (%)	55.5	56.3	1.00
Work in health care sector (%)	37.8	7.9	5.7×10^{-14}
Work with patient contact (%)	36.2	7.3	1.4×10^{-13}
Date of positive SARS-CoV-2 test (median, range)	22 May 2020 (8 Mar 2020 – 12 Aug 2020)	21 Jun 2020 (5 Mar 2020 – 12 Aug 2020)	0.001

496 Characteristics of included men and women with a history of COVID-19 without need of hospitalization
497 confirmed by a SARS-CoV-2-positive PCR.

498 Abbreviations: BMI, body mass index. IQR, interquartile range. PCR, polymerase chain reaction. SARS-CoV-
499 2, severe acute respiratory syndrome coronavirus 2. SD, standard deviation.

500

501
502

Table 2. Characteristics of non-hospitalized symptomatic men and women with COVID-19

	Women (n=148)	Men (n=90)	P-value
Age (mean, SD)	44.0 (15.9)	46.0 (14.8)	0.32
BMI (median, IQR)	24.3 (6.9)	25.5 (4.7)	0.55
Smoking (ever, %)	19.4	15.6	1
Comorbidity (%)	56.0	55.6	1
Work in health care sector (%)	44.0	13.3	8.0x10 ⁻⁷
Work with patient contact (%)	42.6	12.2	6.3x10 ⁻⁷
Contact to someone with positive test for COVID-19 (%)	49.4	49.1	1
Symptom start within a few hours (%)	55.4	52.2	0.24
Date of positive SARS-CoV-2 test (median, range)	12-May-2020 (10-Mar-2020–12-Aug-2020)	11-Jun-2020 (5-Mar-2020–12-Aug-2020)	0.14
Date of symptom onset (median, range)	7-May-2020 (2-Mar-2020–11-Aug-2020)	11-Jun-2020 (26-Feb-2020–13-Aug-2020)	0.09
Time from symptom start to PCR confirmation, days (median, range)	-2 (-23-6)	-1 (-17-6)	0.67
Time from symptom start to questionnaire, days (median, range)	104 (5-202)	69 (7-176)	0.01
Time from symptom start to stop, days (median, range) (n=137)	14 (1-112)	12 (1-138)	0.06

503
504
505
506
507
508

Characteristics of 238 non-hospitalized symptomatic men and women with a history of COVID-19 confirmed by a SARS-CoV-2-positive PCR-test.

Abbreviations: BMI, body mass index. IQR, interquartile range. PCR, polymerase chain reaction. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. SD, standard deviation.

509 **Table 3. Risk of persistent symptoms after COVID-19**

	Persistent symptoms (n=72)	No persistent symptoms (n=113)	Odds ratio (95% CI)	p-value	Adjusted odds ratio (95% CI)*	p-value
Sex** (women, %)	76.4%	54.9%	2.66 (1.38-5.14)	0.003	2.91 (1.32-6.39)	0.008
Age (mean (SD))	47.4 (15.2)	45.4 (15.5)	1.01 (0.99-1.03)	0.38	1.00 (0.97-1.03)	0.97
Smoking (ever, %)***	16.7%	15.0%	1.13 (0.50-2.53)	0.84	0.84 (0.30-2.41)	0.75
BMI (median (IQR))	26.8 (8.6)	24.4 (4.3)	1.11 (1.04-1.18)	0.001	1.13 (1.05-1.22)	0.001
Comorbidity (%)	47.2%	42.3%	1.47 (0.77-2.80)	0.26	1.40 (0.68-2.85)	0.36
Work in health care sector (%)	43.1%	29.5%	1.81 (0.98-3.36)	0.08	1.28 (0.58-2.81)	0.54
Time from symptom start to questionnaire (weeks) (median, range)	16 (5-25)	15 (5-27)	1.01 (0.96-1.06)	0.76	0.99 (0.93-1.06)	0.86

510 *The risk of persistent symptoms vs. no persistent symptoms after four weeks in participants with symptoms
511 in the acute phase and a minimum of four weeks of follow-up from symptom start (n=198) adjusted for: sex,
512 age, smoking, BMI, comorbidity and time from symptom start to questionnaire.
513 **Men as reference group.
514 ***Non-smokers as reference group.
515 Abbreviations: BMI, body mass index. CI, confidence interval. IQR, interquartile range.

516 **Table 4. Overview of studies on persistent symptoms in non-hospitalized COVID-19**

Author	Participants*	Recruitment	Diagnosis of COVID-19	Persistent symptoms				
				Reporting	Definition	Prevalence	Most common	Risk factors
Bliddal (present study)	445 non-hospitalized	PCR-positive cases invited to genetics study	Positive PCR confirmed by national register	Questionnaire at time of inclusion	4 weeks 12 weeks	36% 40%	Fatigue, memory and concentration difficulties, smell loss, shortness of breath	Female, BMI
Cirulli (32) **	233 (8 hospitalized) (3,652 negative controls, 17,474 non-tested)	Population study initiated before COVID-pandemic	Self-reported positive COVID-test	Prospective survey every 4-6 weeks	30 days 60 days 90 days	42.3% 33.8% 24.1%	Anosmia, ageusia, memory loss, and headache	Severity of acute phase, initial dyspnoea
Davis (33)**	3,762 (56.7% non-hospitalized) with illness >28 days	Social media and support groups for long COVID	Suspected or confirmed COVID-19 cases (27% laboratory-confirmed)	Survey distribution via online COVID-19 support groups and social media	28 days 90 days 6 months	100% 96% 65.2%	Fatigue, post-exertional malaise, and cognitive dysfunction	78.9% female responders
Goërtz (36)	2,113 (2,001 non-hospitalized)	Facebook groups for persistent coronavirus and website of Lung Foundation	Confirmed (n=345), symptom-based or suspected COVID-19	Online questionnaire link available in recruitment fora	3 weeks (mean 79±17 days)	99.3%	Fatigue, dyspnoea	Age, number of acute symptoms, previous health status, comorbidities
Patient Research Group (35) **	640 (56.4% no hospital contact)	Online survey on long COVID	Tested for COVID-19 (n=324) or attributing symptoms to COVID-19	Online survey on symptoms and demographics related to COVID-19	Mean ongoing 40 days, recovery 27 days	NA	Shortness of breath, tightness of chest, fatigue, brain fog/concentration challenges (most prevalent at week 4)	76.6% female responders
Petersen (31)	180 (8 hospitalized)	PCR-positive cases invited to long COVID study	Positive PCR	Phone interview(s) at inclusion and follow-up (symptom onset to last interview: mean days 125 (SD 18), range:45-215)	Mean 125 days	53.1% (8.9% severe persistent)	Fatigue, loss of smell and taste, and arthralgias	Number of acute symptoms, age 50-66 years
Sudre (34)**	4,182 incident cases from UK, USA, and Sweden (% hospitalization NA)	Population symptom monitoring during COVID-pandemic	Self-reported positive PCR	Prospective weekly symptom logging in app	4 weeks 8 weeks 12 weeks	13.3% 4.5% 2.3%	Fatigue, headache, dyspnoea and anosmia	Age, BMI, female, hospital assessment
Tenforde (30)	292 outpatients	Random sample of PCR-positive outpatients	Positive PCR at outpatient clinic	Telephone interview 14-21 days after PCR-test	Median 16 (14-21) days	35% of symptomatic participants	Cough, fatigue, congestion, dyspnoea	Age, psychiatric condition, BMI, comorbidities
Walsh-Messinger (37)**	52 students at private university (96 non-COVID students)	Students invited for online survey	Suspected or confirmed (75% PCR-positive)	Online surveys at inclusion	≥28 days	51%	Impaired concentration, headache, rhinitis, exercise intolerance, dyspnoea, sleep impairment, brain fog, appetite loss, fatigue, and chest pain	Female, acute symptom severity

517 *Not included: Studies of outpatients recruited via COVID-units or specialized clinics due to COVID-19-related symptoms (i.e. smell loss) or follow-up, case
518 reports or series, studies without hospitalization or symptom status, non-English language. **Study available online included due to relevance despite unpublished
519 non-peer-reviewed. Abbreviations: NA, not available. PCR, polymerase chain reaction for severe acute respiratory syndrome coronavirus 2.